Antibody responses against heterologous H5N1 strains for an MF59-adjuvanted cell culture–derived H5N1 (aH5n1c) influenza vaccine in adults and older adults

References

• Centers for Disease Control and Prevention. Influenza historic timeline; 2019 Jan 30 [accessed 2022 July 27]. https://www.cdc.gov/flu/pandemic-resources/pandemic-timeline-1930-and-beyond.htm.
   Google Scholar
• Holloway R, Rasmussen SA, Zaza S, Cox NJ, Jernigan DB. Updated preparedness and response framework for influenza pandemics. MMWR Recomm Rep. 2014;63:1–7. PMID: 25254666.
   PubMed Web of Science ®Google Scholar
• Miller MA, Viboud C, Balinska M, Simonsen L. The signature features of influenza pandemics–implications for policy. N Engl J Med. 2009;360:2595–8. doi:10.1056/NEJMp0903906. PMID: 19423872.
   PubMed Web of Science ®Google Scholar
• Homeland Security Council. National strategy for pandemic influenza. Washington (DC): Department of Homeland Security; 2005.
   Google Scholar
• Taubenberger JK, Kash JC. Influenza virus evolution, host adaptation, and pandemic formation. Cell Host & Microbe. 2010;7:440–51. doi:10.1016/j.chom.2010.05.009. PMID: 20542248.
   PubMed Web of Science ®Google Scholar
• Bouvier NM, Palese P. The biology of influenza viruses. Vaccine. 2008;26(Suppl 4):D49–53. doi:10.1016/j.vaccine.2008.07.039. PMID: 19230160.
   PubMed Web of Science ®Google Scholar
• Van Kerkhove MD, Mumford E, Mounts AW, Bresee J, Ly S, Bridges CB, Otte J. Highly pathogenic avian influenza (H5N1): pathways of exposure at the animal-human interface, a systematic review. PLos One. 2011;6:e14582. doi:10.1371/journal.pone.0014582. PMID: 21283678.
   PubMed Web of Science ®Google Scholar
• Rabinowitz P, Perdue M, Mumford E. Contact variables for exposure to avian influenza H5N1 virus at the human-animal interface. Zoonoses Public Health. 2010;57:227–38. doi:10.1111/j.1863-2378.2008.01223.x. PMID: 19486500.
   PubMed Web of Science ®Google Scholar
• Tajudeen YA, Bamigboye NTA, Oladunjoye IO. Emerging strain (H5N8) of highly pathogenic avian influenza virus: an impending pandemic threat. J Infect Dis Epidemiol. 2021;7:217. doi:10.23937/2474-3658/1510217.
   Google Scholar
• World Health Organization. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2023; 2023 Jan 5 [accessed 2023 Feb 23]. https://www.who.int/publications/m/item/cumulative-number-of-confirmed-human-cases-for-avian-influenza-ah5n1-reported-to-who-2003-2022-5-jan-2023.
   Google Scholar
• Fedson DS. Pandemic influenza and the global vaccine supply. Clin Infect Dis. 2003;36:1552–61. doi:10.1086/375056. PMID: 12802755.
   PubMed Web of Science ®Google Scholar
• Stephenson I, Bugarini R, Nicholson KG, Podda A, Wood JM, Zambon MC, Katz JM. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis. 2005;191:1210–15. doi:10.1086/428948. PMID: 15776364.
   PubMed Web of Science ®Google Scholar
• Seubert A, Calabro S, Santini L, Galli B, Genovese A, Valentini S, Aprea S, Colaprico A, D’oro U, Giuliani MM, et al. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci USA. 2011;108:11169–74. doi:10.1073/pnas.1107941108. PMID: 21690334.
   PubMed Web of Science ®Google Scholar
• Seubert A, Monaci E, Pizza M, O’hagan DT, Wack A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol. 2008;180:5402–12. doi:10.4049/jimmunol.180.8.5402. PMID: 18390722.
   PubMed Web of Science ®Google Scholar
• Schultze V, D’agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine. 2008;26:3209–22. doi:10.1016/j.vaccine.2008.03.093. PMID: 18462843.
   PubMed Web of Science ®Google Scholar
• Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med. 2010;2:15ra15. doi:10.1126/scitranslmed.3000624. PMID: 20371470.
   Web of Science ®Google Scholar
• Calabro S, Tortoli M, Baudner BC, Pacitto A, Cortese M, O’hagan DT, De Gregorio E, Seubert A, Wack A. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine. 2011;29:1812–23. doi:10.1016/j.vaccine.2010.12.090. PMID: 21215831.
   PubMed Web of Science ®Google Scholar
• Vono M, Taccone M, Caccin P, Gallotta M, Donvito G, Falzoni S, Palmieri E, Pallaoro M, Rappuoli R, Di Virgilio F, et al. The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination. Proc Natl Acad Sci USA. 2013;110:21095–100. doi:10.1073/pnas.1319784110. PMID: 24324152.
   PubMed Web of Science ®Google Scholar
• O’hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59—an innately attractive adjuvant formulation. Vaccine. 2012;30:4341–8. doi:10.1016/j.vaccine.2011.09.061. PMID: 22682289.
   PubMed Web of Science ®Google Scholar
• Khurana S, Verma N, Yewdell JW, Hilbert AK, Castellino F, Lattanzi M, Del Giudice G, Rappuoli R, Golding H. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med. 2011;3:85ra48. doi:10.1126/scitranslmed.3002336. PMID: 21632986.
   PubMed Web of Science ®Google Scholar
• Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecchi PL, di Giovanni P, Sticchi L, Gentile C, et al. MF59®-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One. 2009;4:e4384. doi:10.1371/journal.pone.0004384. PMID: 19197383.
   PubMed Web of Science ®Google Scholar
• Galli G, Hancock K, Hoschler K, DeVos J, Praus M, Bardelli M, Malzone C, Castellino F, Gentile C, McNally T, et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci USA. 2009;106:7962–7. doi:10.1073/pnas.0903181106. PMID: 19416838.
   PubMed Web of Science ®Google Scholar
• O’hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Exp Rev Vaccines. 2007;6:699–710. doi:10.1586/14760584.6.5.699. PMID: 17931151.
   PubMed Web of Science ®Google Scholar
• Knuf M, Leroux-Roels G, Rumke HC, Abarca K, Rivera L, Lattanzi M, Pedotti P, Arora A, Kieninger-Baum D, Della Cioppa G. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age. Vaccine. 2015;33:174–81. doi:10.1016/j.vaccine.2014.10.085. PMID: 25444803.
   PubMed Web of Science ®Google Scholar
• Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine. 2009;27:6959–65. doi:10.1016/j.vaccine.2009.08.101. PMID: 19751689.
   PubMed Web of Science ®Google Scholar
• Frey SE, Shakib S, Chanthavanich P, Richmond P, Smith T, Tantawichien T, Kittel C, Jaehnig P, Mojares Z, Verma B, et al. Safety and immunogenicity of MF59-adjuvanted cell culture–Derived A/H5N1 subunit influenza virus vaccine: dose-finding clinical trials in adults and the elderly. Open Forum Infect Dis. 2019;6:ofz107. doi:10.1093/ofid/ofz107. PMID: 30968056.
   PubMed Web of Science ®Google Scholar
• Hatz C, Cramer JP, Vertruyen A, Schwarz TF, von Sonnenburg F, Borkowski A, Lattanzi M, Hilbert AK, Cioppa GD, Leroux-Roels G. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations. Vaccine. 2012;30:4820–7. doi:10.1016/j.vaccine.2012.05.013. PMID: 22626675.
   PubMed Web of Science ®Google Scholar
• Keitel W, Groth N, Lattanzi M, Praus M, Hilbert AK, Borkowski A, Tsai TF. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine. 2010;28:840–8. doi:10.1016/j.vaccine.2009.10.019. PMID: 19835829.
   PubMed Web of Science ®Google Scholar
• Izurieta HS, Chillarige Y, Kelman J, Wei Y, Lu Y, Xu W, Lu M, Pratt D, Chu S, Wernecke M, et al. Relative effectiveness of cell-cultured and egg-based influenza vaccines among elderly persons in the United States, 2017–2018. J Infect Dis. 2019;220:1255–64. doi:10.1093/infdis/jiy716. PMID: 30561688.
   PubMed Web of Science ®Google Scholar
• Eick-Cost A, Hu Z. Relative effectiveness of cell-based influenza vaccines compared to egg-based influenza vaccines, active component U.S. Service members, 2017-18 season. International Conference on Emerging Infectious Diseases; 2018; Atlanta (GA). 54. Abstr. 129.
   Google Scholar
• Klein NP, Fireman B, Goddard K, Zerbo O, Asher J, Zhou J, King J, Lewis N. Vaccine effectiveness of Flucelvax relative to inactivated influenza vaccine during the 2017-18 influenza season in Northern California [abstract]. Open Forum Infect Dis. 2018;5(Supplement 1):S764. doi:10.1093/ofid/ofy229.2189. PMID: 629442678.
   Google Scholar
• Barr IG, Donis RO, Katz JM, McCauley JW, Odagiri T, Trusheim H, Tsai TF, Wentworth DE. Cell culture-derived influenza vaccines in the severe 2017-2018 epidemic season: a step towards improved influenza vaccine effectiveness. NPJ Vaccines. 2018;3:44. doi:10.1038/s41541-018-0079-z. PMID: 30323955.
   PubMed Web of Science ®Google Scholar
• Ansaldi F, Bacilieri S, Durando P, Sticchi L, Valle L, Montomoli E, Icardi G, Gasparini R, Crovari P. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine. 2008;26:1525–9. doi:10.1016/j.vaccine.2008.01.019. PMID: 18294741.
   PubMed Web of Science ®Google Scholar
• Ansaldi F, Zancolli M, Durando P, Montomoli E, Sticchi L, Del Giudice G, Icardi G. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine. 2010;28:4123–9. doi:10.1016/j.vaccine.2010.04.030. PMID: 20433807.
   PubMed Web of Science ®Google Scholar
• Nicolay U, Heijnen E, Nacci P, Patriarca PA, Leav B. Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults ≥65 years of age: meta-analysis of cumulative clinical experience. Int J Infect Dis. 2019;85:S1–9. doi:10.1016/j.ijid.2019.03.026. PMID: 30926542.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, Baehner F, Borkowski A, Tsai TF, Clemens R. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med. 2011;365:1406–16. doi:10.1056/NEJMoa1010331. PMID: 21995388.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Kirstein J, Go GD, Leav B, Ruzycky ME, Isakov L, de Bruijn M, Oberye J, Heijnen E. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial. Lancet Respir Med. 2018;6:345–56. doi:10.1016/s2213-2600(18)30108-5. PMID: 29631857.
   PubMed Web of Science ®Google Scholar
• van Baalen CA, Els C, Sprong L, van Beek R, van der Vries E, Osterhaus AD, Rimmelzwaan GF. Detection of nonhemagglutinating influenza a(h3) viruses by enzyme-linked immunosorbent assay in quantitative influenza virus culture. J Clin Microbiol. 2014;52:1672–7. doi:10.1128/jcm.03575-13. PMID: 24622097.
   PubMed Web of Science ®Google Scholar
• Nakowitsch S, Waltenberger AM, Wressnigg N, Ferstl N, Triendl A, Kiefmann B, Montomoli E, Lapini G, Sergeeva M, Muster T, et al. Egg- or cell culture-derived hemagglutinin mutations impair virus stability and antigen content of inactivated influenza vaccines. Biotechnol J. 2014;9:405–14. doi:10.1002/biot.201300225. PMID: 24323790.
   PubMed Web of Science ®Google Scholar
• Hegde NR. Cell culture-based influenza vaccines: a necessary and indispensable investment for the future. Human Vaccin Immunother. 2015;11:1223–34. doi:10.1080/21645515.2015.1016666. PMID: 25875691.
   PubMed Web of Science ®Google Scholar
• van Baalen CA, Jeeninga RE, Penders GH, van Gent B, van Beek R, Koopmans MP, Rimmelzwaan GF. ViroSpot microneutralization assay for antigenic characterization of human influenza viruses. Vaccine. 2017;35:46–52. doi:10.1016/j.vaccine.2016.11.060. PMID: 27899226.
   PubMed Web of Science ®Google Scholar
• Trombetta CM, Perini D, Mather S, Temperton N, Montomoli E. Overview of serological techniques for influenza vaccine evaluation: past, present and future. Vaccines (Basel). 2014;2:707–34. doi:10.3390/vaccines2040707. PMID: 26344888.
   PubMedGoogle Scholar
• Heeringa M, Leav B, Smolenov I, Palladino G, Isakov L, Matassa V. Comparability of titers of antibodies against seasonal influenza virus strains as determined by hemagglutination inhibition and microneutralization assays. J Clin Microbiol. 2020;58:e00750–00720. doi:10.1128/JCM.00750-20. PMID: 32493784.
   PubMed Web of Science ®Google Scholar
• Verschoor CP, Singh P, Russell ML, Bowdish DM, Brewer A, Cyr L, Ward BJ, Loeb M. Microneutralization assay titres correlate with protection against seasonal influenza H1N1 and H3N2 in children. Plos One. 2015;10:e0131531. doi:10.1371/journal.pone.0131531. PMID: 26107625.
   PubMed Web of Science ®Google Scholar
• Trombetta CM, Ulivieri C, Cox RJ, Remarque EJ, Centi C, Perini D, Piccini G, Rossi S, Marchi S, Montomoli E. Impact of erythrocyte species on assays for influenza serology. J Prev Med Hyg. 2018;59:E1–e7. doi:10.15167/2421-4248/jpmh2018.59.1.870. PMID: 29938233.
   PubMedGoogle Scholar